Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
Minisola
Salvatore
S
Scillitani
Alfredo
A
Romagnoli
Elisabetta
E
D019386:Alendronate / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024042:Collagen Type I / Q000652:urine; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D006887:Hydroxycholecalciferols / Q000494:pharmacology* / Q000627:therapeutic use; D006934:Hypercalcemia / Q000175:diagnosis*; D010024:Osteoporosis / Q000139:chemically induced / Q000517:prevention & control*; D010455:Peptides / Q000652:urine
D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D005938:Glucocorticoids; D006887:Hydroxycholecalciferols; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; C008088:alfacalcidol; D019386:Alendronate